Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00179062
Status:
COMPLETED
Last Update Posted:
2008-08-26
First Post:
2005-09-13
Brief Title:
Effects of Risperidone and Olanzapine on Patients With Schizophrenia Schizoaffective Disorder Major Depression or Bipolar Disorder
Sponsor:
Vanderbilt University
Organization:
Vanderbilt University
Study Overview
Official Title:
Effects of Risperidone and Olanzapine on Weight Gain Physical Health and Outcome in a Community Sample of Severity and Persistently Ill Patients
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This twelve month open-label study considers the effect of Risperdal risperidone versus Zyprexa olanzapine on weight gain physical health and outcome in a population of those diagnosed with schizophrenia schizoaffective disorder major depression or bipolar disorder with psychotic features This study evaluates symptom response as well as general health indicators such as body mass index glucose prolactin and cholesterol levels at baseline month M1 M3 M6 and M12
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None